Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 31 to 40 of 75

TitleReference numberPublishedLast updated
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancerTA781
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancerTA770
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancerTA724
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapyTA713
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancerTA705
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancerTA683
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitorTA670
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)TA662
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapyTA655
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancerTA653

Results per page

  1. 10
  2. 25
  3. 50
  4. All